Benjamin K Fisher

US Patent:

20110086834, Apr 14, 2011

Filed:

Jun 26, 2009

Appl. No.:

12/997868

Inventors:

Guoqing Chen - Palo Alto CA, US
Timothy D. Cushing - Pacifica CA, US
Paul Faulder - Cheshire, GB
Benjamin Fisher - San Mateo CA, US
Xiao He - Foster City CA, US
Kexue Li - Mountain View CA, US
Zhihong Li - Millbrae CA, US
Wen Liu - Foster City CA, US
Lawrence R. Mcgee - Pacifica CA, US
Vatee Pattaropong - Burlingame CA, US
Jennifer L. Seganish - Scotch Plains NJ, US
Youngshook Shin - Emeryville CA, US
Zhulun Wang - Palo Alto CA, US

Assignee:

AMGEN INC. - Thousand Oaks CA

International Classification:

A61K 31/506
C07D 413/14
C07D 403/14
C07D 401/14
C07D 417/14
C07D 413/04
C07D 403/04
C07D 409/14
C07D 491/107
C07D 498/10
C07D 473/16
C07D 487/04
C07D 407/14
C07D 239/48
C07D 471/10
C07D 495/10
C07D 487/14
A61K 31/497
A61K 31/433
A61K 31/53
A61K 31/4439
A61K 31/427
A61K 31/52
A61K 31/5377
A61K 31/505
A61K 31/519
A61K 31/55
A61P 35/00
A61P 35/02
A61P 37/06
A61P 11/06
A61P 17/00
A61P 19/02
A61P 25/28
A61P 11/00
A61P 1/00
A61P 29/00

US Classification:

51421016, 544324, 544295, 548128, 544405, 544209, 544230, 544 71, 544212, 5462697, 544277, 548181, 544333, 544122, 544331, 544323, 544247, 540521, 544131, 544328, 514275, 51425505, 514361, 514245, 514256, 5142305, 514339, 514365, 5142632, 5142352, 514257, 51421206, 5142372

Abstract:

Selected compounds are effective for prophylaxis and treatment of inflammation and inflammatory disorders, such as NIK-mediated disorders. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, inflammation and the like.

US Patent:

20130085131, Apr 4, 2013

Filed:

Jun 30, 2011

Appl. No.:

13/702368

Inventors:

Minna Bui - Oakland CA, US
Benjamin Fisher - San Mateo CA, US
Xiaolin Hao - Foster City CA, US
Brian Lucas - San Francisco CA, US

Assignee:

Amgen Inc. - Thousand Oaks CA

International Classification:

C07D 413/14
C07D 401/14
C07D 401/12

US Classification:

51421018, 544328, 514256, 544122, 5142352, 544295, 51425218

Abstract:

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with pi 110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.

US Patent:

20130267526, Oct 10, 2013

Filed:

Dec 16, 2011

Appl. No.:

13/994332

Inventors:

Yi Chen - San Jose CA, US
Timothy David Cushing - Pacifica CA, US
Benjamin Fisher - San Mateo CA, US
Felix Gonzalez Lopez De Turiso - San Mateo CA, US
Xiaolin Hao - Foster City CA, US
Youngsook Shin - Emeryville CA, US

Assignee:

Amgen, Inc. - Thousand Oaks

International Classification:

C07D 471/04
C07D 473/00
C07D 403/12

US Classification:

514249, 544328, 514256, 544295, 51426322, 544277

Abstract:

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110 activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.

US Patent:

20160333017, Nov 17, 2016

Filed:

Jul 26, 2016

Appl. No.:

15/219624

Inventors:

- Thousand Oaks CA, US
Yi CHEN - San Jose CA, US
Timothy David CUSHING - Pacifica CA, US
Jason A. DUQUETTE - Millbrae CA, US
Benjamin FISHER - San Mateo CA, US
Felix GONZALEZ LOPEZ DE TURISO - Cambridge MA, US
Xiaolin HAO - Foster City CA, US
Xiao HE - Foster City CA, US
Michael G. JOHNSON - San Francisco CA, US
Brian LUCAS - Arlington MA, US

Assignee:

AMGEN INC. - Thousand Oaks CA

International Classification:

C07D 487/04
C07D 401/12
C07D 471/04
C07D 473/34
C07D 401/14

Abstract:

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.

US Patent:

20140350244, Nov 27, 2014

Filed:

Aug 7, 2014

Appl. No.:

14/453842

Inventors:

- Thousand Oaks CA, US
Kang DAI - Albany CA, US
John EKSTEROWICZ - San Francisco CA, US
Pingchen FAN - Fremont CA, US
Benjamin FISHER - San Mateo CA, US
Jiasheng FU - Foster City CA, US
Kexue LI - Mountain View CA, US
Zhihong LI - Millbrae CA, US
Lawrence R. MCGEE - Pacifica CA, US
Rajiv SHARMA - Fremont CA, US
Xiaodong WANG - Millbrae CA, US
Dustin L. MCMINN - Pacifica CA, US
Jeffrey T. MIHALIC - San Francisco CA, US
Jeffrey DEIGNAN - San Francisco CA, US

International Classification:

C07D 471/14
C07D 498/10
C07D 491/107
C07D 471/04
C07D 487/14

US Classification:

540575, 544251, 544238, 544250, 544 582, 544115, 544234, 544230, 544231, 544 71

Abstract:

Compounds, pharmaceutical compositions and methods are provided that are useful in the treatment of CDK4-mediated disorders, such as cancer. The subject compounds are fused pyridine, pyrimide and triazine derivatives.